Clinical relevance of different IgG and IgM serum antibody responses to Borrelia burgdorferi after antibiotic therapy for erythema migrans: Long-term follow-up study of 113 patients

Archives of Dermatology

Volumn 142, Issue 7, 2006, Pages 862-868

  Glatz, Martin ^a   Golestani, Marjaneh ^a   Kerl, Helmut ^a   Müllegger, Robert R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ANTIBODY TITER; ARTICLE; BORRELIA BURGDORFERI; CHILD; CONTROLLED STUDY; ERYTHEMA CHRONICUM MIGRANS; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BORRELIA BURGDORFERI; CEFTRIAXONE; CHILD; DOXYCYCLINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHEMA CHRONICUM MIGRANS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MINOCYCLINE; PENICILLIN V; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 33746036517     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.7.862     Document Type: Article

References (43)

1. Steere AC. Lyme disease. N Engl J Med. 2001;345:115-125.
2. Dennis DT, Hayes EB. Epidemiology of Lyme borreliosis. In: Gray J, Kahl O, Lane RS, Stanek G, eds. Lyme Borreliosis: Biology, Epidemiology and Control. Wallingford, England: CABI Publishing; 2002:251-280.
3. Steere AC, Bartenhagen NH, Craft JE, et al. The early clinical manifestations of Lyme disease. Ann Intern Med. 1983;99:76-82.
4. Stanek G, O'Connell S, Cimmino M, et al. European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr. 1996;108:741-747.
5. Nadelman RB, Nowakowski J, Forseter G, et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med. 1996;100:502-508.
6. Strle F, Nelson JA, Ruzic-Sabljic E, et al. European Lymeborreliosis: 231 culture-confirmed cases involving patients with erythema migrans. Clin Infect Dis. 1996;23:61-65.
7. Stanek G, Strle F. Lyme borreliosis. Lancet. 2003;362:1639-1647.
8. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med. 1983;99:22-26.
9. Strle F, Maraspin V, Lotric-Furlan S, Ruzic-Sabljic E, Cimperman J. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection. 1996;24:64-68.
10. Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med. 2002;136:421-428.
11. Nowakowski J, Nadelman RB, Sell R, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med. 2003;115:91-96.
12. Wormser GP, Nadelmann RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease: guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2000;31(suppl):1-14.
13. Bennet L, Danell S, Berglund J. Clinical outcome of erythema migrans after treatment with phenoxymethyl penicillin. Scand J Infect Dis. 2003;35:129-131.
14. Hulshof MM, Vandenbrouke JP, Nohlmans LM, Spanjaard L, Bavnick JN, Dijkmans BA. Long-term prognosis in patients treated for erythema chronicum migrans and acrodermatitis chronica atrophicans. Arch Dermatol. 1997;133:33-37.
15. Weber K. Treatment failure in erythema migrans: a review. Infection. 1996;24:73-75.
16. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345:85-92.
17. Picken MM, Picken RN, Han D, et al. A two-year prospective study to compare culture and polymerase chain reaction amplification for the detection and diagnosis of Lyme borreliosis. Mol Pathol. 1997;50:186-193.
18. Lebech AM, Hansen K, Bandrup F, Clemmensen O, Halkier-Sorensen L. Diagnostic value of PCR for detection of Borrelia burgdorferi DNA in clinical specimens from patients with erythema migrans and Lyme neuroborreliosis. Mol Diagn. 2000;5:139-150.
19. Muellegger RR, Zoechling N, Soyer HP, et al. No detection of Borrelia burgdorferi-specific DNA in erythema migrans lesions after minocycline treatment. Arch Dermatol. 1995;131:678-682.
20. Müllegger RR. Dermatological manifestations of Lyme borreliosis. Eur J Dermatol. 2004;14:296-309.
21. Hansen K, Hindersson P, Strandberg Pedersen N. Measurement of antibodies to the Borrelia burgdorferi flagellum improves serodiagnosis in Lyme disease. J Clin Microbiol. 1988;26:338-346.
22. Coleman JL, Benach JL. Isolation of antigenic components from the Lyme disease spirochete: their role in early diagnosis. J Infect Dis. 1987;155:756-765.
23. Wilske B, Preac-Mursic V, Schierz G. Antigenic variability of Borrelia burgdorferi. Ann N Y Acad Sci. 1988;539:126-143.
24. Hansen K, Åsbrink E. Serodiagnosis of erythema migrans and acrodermatitis chronica atrophicans by the Borrelia burgdorferi flagellum enzyme-linked immunosorbent assay. J Clin Microbiol. 1989;27:545-551.
25. Hansen K, Pii K, Lebech AM. Improved immunoglobulin M serodiagnosis in Lyme borreliosis by using a mu-capture enzyme-linked immunosorbent assay with biotinylated Borrelia burgdorferi flagella. J Clin Microbiol. 1991;29:166-173.
26. Åsbrink E, Hovmark A, Hederstedt B. Serologic studies of erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans with indirect immunofluorescence and enzyme-linked immunosorbent assays. Acta Derm Venereol. 1985;65:509-514.
27. Weber K, Preac-Mursic V, Neubert U, et al. Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans. Ann N Y Acad Sci. 1988;539:324-345.
28. Weber K, Preac-Mursic V, Wilske B, Thurmayr R, Neubert U, Scherwitz C. A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis. Infection. 1990;18:91-96.
29. Feder HM Jr, Gerber MA, Luger SW, Ryan RW. Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. Clin Infect Dis. 1992;15:788-793.
30. Hammers-Berggren S, Lebech AM, Karlsson M, Svenungsson B, Hansen K, Stiernstedt G. Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis. J Clin Microbiol. 1994;32:1519-1525.
31. Shadick NA, Phillips CB, Logigian EL, et al. The long-term clinical outcome of Lyme disease. Ann Intern Med. 1994;121:560-567.
32. Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol. 1996;34:1-9.
33. Stanek G, Breier F, Menzinger G, Schaar B, Hafner M, Partsch H. Erythema migrans and serodiagnosis by enzyme immunoassay and immunoblot with three Borrelia species. Wien Klin Wochenschr. 1999;111:951-956.
34. Lomholt H, Lebech AM, Hansen K, Bandrup F, Halkier-Sorensen L. Long-term serological follow-up of patients treated for chronic cutaneous borreliosis or culturepositive erythema migrans. Acta Derm Venereol. 2000;80:362-366.
35. Kalish RA, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis. 2001;33:780-785.
36. Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Thomas J, Golightly MG. Seronegative Lyme disease: dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi. N Engl J Med. 1988;319:1441-1446.
37. Rahn DW, Malawista SE. Lyme disease: recommendations for diagnosis and treatment. Ann Intern Med. 1991;114:472-481.
38. Åsbrink E. Cutaneous manifestations of Lyme borreliosis: clinical definitions and differential diagnoses. Scand J Infect Dis Suppl. 1991;77:44-50.
39. Lipsker D, Lieber-Mbomeyo A, Hedelin G. How accurate is a clinical diagnosis of erythema chronicum migrans? prospective study comparing the diagnostic accuracy of general practitioners and dermatologists in an area where Lyme borreliosis is endemic. Arch Dermatol. 2004;140:620-621.
40. Oksi J, Marttila H, Soini H, Aho H, Uksila J, Viljanen MK. Early dissemination of Borrelia burgdorferi without generalized symptoms in patients with erythema migrans. APMIS. 2001;109:581-588.
41. Strle F, Nadelman RB, Cimperman J, et al. Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med. 1999;130:32-36.
42. Berger BW, Johnson RC, Kodner C, Coleman L. Failure of Borrelia burgdorferi to survive in the skin of patients with antibiotic-treated Lyme disease. J Am Acad Dermatol. 1992;27:34-37.
43. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B-cells. Science. 2002;298:2199-2202.